Literature DB >> 32420101

Endomyocardial fibrosis.

Chukwuemeka Daniel Iroegbu1, Wangping Chen1, Xun Wu1, Ming Wu1, Jinfu Yang1.   

Abstract

BACKGROUND: Endomyocardial fibrosis (EMF) is a neglected cardiovascular disease of poverty which carries a poor prognosis with no specific treatment affecting mainly children and young adults. Here, we report our 10-year experience in the therapeutic management and surgical treatment for EMF.
METHODS: From February 2009 to 2019 March, 55 patients diagnosed with EMF from our cardiology unit underwent surgical repair at our department's pediatric surgical division. There were 35 male, and 20 female patients whose ages varied from 1 year 2 months to 12 years mean age 5.7 (±3.2). We designed the study aimed at assessing the cardio-structural abnormalities and coronary vascular changes faced with EMF patients using echocardiography, and coronary angiography with a detailed and thorough surgical examination of each case.
RESULTS: Of the 55 operated patients, 1 had mild lesions, 26 had moderate lesions, and 28 had severe heart disease. All but one patient was in NYHA functional class III or IV at the time of surgery. All but one female patient with mild ventricular lesions and no valvular involvement had severe atrioventricular valve regurgitation with valves considered suitable for both replacements; 45 patients mean age 6.0 (±3.1) and repair nine patients mean age 3.8 (±2.9). The mean endocardial thickness was 3,000 (±1519) µm.
CONCLUSIONS: The echocardiographic changes corresponded well to the findings on surgery and histopathology. The coronary changes seen included a spectrum of fibrin deposition, medial sclerosis and degeneration, and the formation of plexiform lesions. Surgically evaluating the resected cardiac tissue might help improve disease management. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  Endomyocardial fibrosis (EMF); endemic disease; endocardial stripping; genetic susceptibility; health services accountability; heart failure (HF)

Year:  2020        PMID: 32420101      PMCID: PMC7225420          DOI: 10.21037/cdt.2020.02.10

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  56 in total

1.  Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council.

Authors:  Leo Lopez; Steven D Colan; Peter C Frommelt; Gregory J Ensing; Kathleen Kendall; Adel K Younoszai; Wyman W Lai; Tal Geva
Journal:  J Am Soc Echocardiogr       Date:  2010-05       Impact factor: 5.251

2.  [Heart transplantation in a patient with endomyocardial fibrosis].

Authors:  Humberto F G de Freitas; Pedro Paulo Neves de Castro; Paulo Roberto Chizzola; Edimar Alcides Bocchi
Journal:  Arq Bras Cardiol       Date:  2005-01       Impact factor: 2.000

3.  Helminth associated hypereosinophilia and tropical endomyocardial fibrosis (EMF) in Nigeria.

Authors:  J J Andy; P O Ogunowo; N A Akpan; C O Odigwe; I A Ekanem; R A Esin
Journal:  Acta Trop       Date:  1998-05       Impact factor: 3.112

4.  Chemokines: leucocyte recruitment and activation cytokines.

Authors:  D H Adams; A R Lloyd
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

5.  Clinical course of endomyocardial fibrosis.

Authors:  P N Gupta; M S Valiathan; K G Balakrishnan; C C Kartha; M K Ghosh
Journal:  Br Heart J       Date:  1989-12

6.  Myocardial fibrosis in isolated left ventricular non-compaction and its relation to disease severity.

Authors:  Gaetano Nucifora; Giovanni D Aquaro; Alessandro Pingitore; Pier Giorgio Masci; Massimo Lombardi
Journal:  Eur J Heart Fail       Date:  2011-01-04       Impact factor: 15.534

Review 7.  Endomyocardial fibrosis, a case for the tropical doctor.

Authors:  C C Kartha
Journal:  Cardiovasc Res       Date:  1995-11       Impact factor: 10.787

Review 8.  Recent advances in the epidemiology, diagnosis and treatment of endomyocardial fibrosis in Africa.

Authors:  Ana Olga H Mocumbi; Ayodele O Falase
Journal:  Heart       Date:  2013-05-16       Impact factor: 5.994

9.  Persisting hypereosinophilia and myocardial activity in the fibrotic stage of endomyocardial disease.

Authors:  A Frustaci; A K Abdulla; G Possati; U Manzoli
Journal:  Chest       Date:  1989-09       Impact factor: 9.410

Review 10.  Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection.

Authors:  David S Celermajer; Clara K Chow; Eloi Marijon; Nicholas M Anstey; Kam S Woo
Journal:  J Am Coll Cardiol       Date:  2012-08-01       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.